552 related articles for article (PubMed ID: 24162158)
1. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Prat A; Karginova O; Parker JS; Fan C; He X; Bixby L; Harrell JC; Roman E; Adamo B; Troester M; Perou CM
Breast Cancer Res Treat; 2013 Nov; 142(2):237-55. PubMed ID: 24162158
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
[TBL] [Abstract][Full Text] [Related]
3. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties.
Sarrio D; Franklin CK; Mackay A; Reis-Filho JS; Isacke CM
Stem Cells; 2012 Feb; 30(2):292-303. PubMed ID: 22102611
[TBL] [Abstract][Full Text] [Related]
4. Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity.
Kim J; Villadsen R; Sørlie T; Fogh L; Grønlund SZ; Fridriksdottir AJ; Kuhn I; Rank F; Wielenga VT; Solvang H; Edwards PA; Børresen-Dale AL; Rønnov-Jessen L; Bissell MJ; Petersen OW
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6124-9. PubMed ID: 22454501
[TBL] [Abstract][Full Text] [Related]
5. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.
Chan SR; Vermi W; Luo J; Lucini L; Rickert C; Fowler AM; Lonardi S; Arthur C; Young LJ; Levy DE; Welch MJ; Cardiff RD; Schreiber RD
Breast Cancer Res; 2012 Jan; 14(1):R16. PubMed ID: 22264274
[TBL] [Abstract][Full Text] [Related]
6. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
7. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models.
Melchor L; Molyneux G; Mackay A; Magnay FA; Atienza M; Kendrick H; Nava-Rodrigues D; López-García MÁ; Milanezi F; Greenow K; Robertson D; Palacios J; Reis-Filho JS; Smalley MJ
J Pathol; 2014 Jun; 233(2):124-37. PubMed ID: 24615332
[TBL] [Abstract][Full Text] [Related]
8. Normal Breast-Derived Epithelial Cells with Luminal and Intrinsic Subtype-Enriched Gene Expression Document Interindividual Differences in Their Differentiation Cascade.
Kumar B; Prasad M; Bhat-Nakshatri P; Anjanappa M; Kalra M; Marino N; Storniolo AM; Rao X; Liu S; Wan J; Liu Y; Nakshatri H
Cancer Res; 2018 Sep; 78(17):5107-5123. PubMed ID: 29997232
[TBL] [Abstract][Full Text] [Related]
9. Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature.
Franks SE; Campbell CI; Barnett EF; Siwicky MD; Livingstone J; Cory S; Moorehead RA
Oncogene; 2012 Jul; 31(27):3298-309. PubMed ID: 22020329
[TBL] [Abstract][Full Text] [Related]
10. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells.
Pommier SJ; Quan GG; Christante D; Muller P; Newell AE; Olson SB; Diggs B; Muldoon L; Neuwelt E; Pommier RF
Ann Surg Oncol; 2010 Feb; 17(2):613-23. PubMed ID: 19838757
[TBL] [Abstract][Full Text] [Related]
11. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.
Sabatier R; Finetti P; Guille A; Adelaide J; Chaffanet M; Viens P; Birnbaum D; Bertucci F
Mol Cancer; 2014 Oct; 13():228. PubMed ID: 25277734
[TBL] [Abstract][Full Text] [Related]
12. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.
Herschkowitz JI; Zhao W; Zhang M; Usary J; Murrow G; Edwards D; Knezevic J; Greene SB; Darr D; Troester MA; Hilsenbeck SG; Medina D; Perou CM; Rosen JM
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2778-83. PubMed ID: 21633010
[TBL] [Abstract][Full Text] [Related]
13. TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer.
Seksenyan A; Kadavallore A; Walts AE; de la Torre B; Berel D; Strom SP; Aliahmad P; Funari VA; Kaye J
BMC Cancer; 2015 Jan; 15():22. PubMed ID: 25632947
[TBL] [Abstract][Full Text] [Related]
14. Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis.
Leth-Larsen R; Terp MG; Christensen AG; Elias D; Kühlwein T; Jensen ON; Petersen OW; Ditzel HJ
Mol Med; 2012 Sep; 18(1):1109-21. PubMed ID: 22692575
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland.
Shehata M; Teschendorff A; Sharp G; Novcic N; Russell IA; Avril S; Prater M; Eirew P; Caldas C; Watson CJ; Stingl J
Breast Cancer Res; 2012 Oct; 14(5):R134. PubMed ID: 23088371
[TBL] [Abstract][Full Text] [Related]
16. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
[TBL] [Abstract][Full Text] [Related]
17. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice.
Morel AP; Hinkal GW; Thomas C; Fauvet F; Courtois-Cox S; Wierinckx A; Devouassoux-Shisheboran M; Treilleux I; Tissier A; Gras B; Pourchet J; Puisieux I; Browne GJ; Spicer DB; Lachuer J; Ansieau S; Puisieux A
PLoS Genet; 2012; 8(5):e1002723. PubMed ID: 22654675
[TBL] [Abstract][Full Text] [Related]
18. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.
Lim E; Vaillant F; Wu D; Forrest NC; Pal B; Hart AH; Asselin-Labat ML; Gyorki DE; Ward T; Partanen A; Feleppa F; Huschtscha LI; Thorne HJ; ; Fox SB; Yan M; French JD; Brown MA; Smyth GK; Visvader JE; Lindeman GJ
Nat Med; 2009 Aug; 15(8):907-13. PubMed ID: 19648928
[TBL] [Abstract][Full Text] [Related]
19. Re-definition of claudin-low as a breast cancer phenotype.
Fougner C; Bergholtz H; Norum JH; Sørlie T
Nat Commun; 2020 Apr; 11(1):1787. PubMed ID: 32286297
[TBL] [Abstract][Full Text] [Related]
20. TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer.
Bruna A; Greenwood W; Le Quesne J; Teschendorff A; Miranda-Saavedra D; Rueda OM; Sandoval JL; Vidakovic AT; Saadi A; Pharoah P; Stingl J; Caldas C
Nat Commun; 2012; 3():1055. PubMed ID: 22968701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
